Current trials of cytotoxic and targeted agents in breast cancer: The caveat of radiotherapy

Annals of Oncology

Volumn 22, Issue 5, 2011, Pages 1243-1244

  Chargari, C ^a   Levy, A ^b   Vedrine L ^a   Magne N ^c  

^a University of Paris Descartes   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Institut de Cancerologie de la Loire   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL (TOPIC); HUMAN; IONIZING RADIATION; LETTER; PRIORITY JOURNAL;

EID: 79955517405     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq787     Document Type: Letter

References (5)

1. Verma S, Ewer MS. Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer? Ann Oncol 2010 Nov 22 [epubahead of print] doi:101093/annonc/mdq607.
2. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 2000; 355: 1757-1570.
3. Magné N, Vé drine L, Chargari C. Impact on cardiac toxicity with trastuzumab and radiotherapy: the question is still ongoing. J Clin Oncol 2009; 27: 239.
4. Suter TM, Procter M, van Veldhuisen DJ et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25: 3859-3865.
5. Feng M, Moran JM, Koelling T et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys 2011; 79: 10-18.